ArticleWiener klinische Wochenschrift2023
Patient adherence to fully reimbursed proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) treatment.
Alissia Stummer et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it